LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’
LIXTE is advancing a first-in-class PP2A inhibitor platform designed to enhance, rather than replace, established chemotherapy and immunotherapy regimens. The company is conducting multiple active clinical trials in solid tumors with significant unmet medical need, supported by academic and industry collaborations. LIXTE’s scientific strategy is protected by a comprehensive patent portfolio, with management noting no known direct competitors targeting PP2A inhibition. Strategic actions in 2025, including the acquisition of Liora Technologies and a registered direct offering completed in December 2025, reflect an effort to broaden capabilities and strengthen operational flexibility. Expansion of the ovarian clear cell carcinoma trial in December…